Investor Updates

Latest Financial Results

Q3 2022

Quarter Ended September 30, 2022

Latest Annual Filing

For Fiscal Year Ending December 31, 2021

Company Overview

NightHawk Biosciences is a fully integrated biopharmaceutical to streamline the creation of innovative medical countermeasures, breaking through barriers that prolong drug development. Our ecosystem is driven by the discovery efforts of SkunkWorx Bio, Inc, the development and commercial expertise of Elusys Therapeutics, Inc., and our in-house contract research and development biomanufacturing organization (CDMO) Scorpius Biological Services. This empowers us to bring our ideas to life with efficient control, superior quality, and uncharacteristic agility.

Stock Snapshot

IR Contacts


Nighthawk Biosciences, Inc.
627 Davis Drive
Suite 300
Morrisville, NC 27560
T: +1 919 240 7133

Transfer Agent

Continental Stock Transfer & Trust Company
17 Battery Place, 8th Floor
New York, NY 10004
T: +1 212 509 4000